Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(56,211) | $(36,846) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Stock-based compensation | 5,858 | 3,451 |
| Depreciation | 44 | 19 |
| Non-cash lease expense | 273 | 138 |
| Net amortization of premiums and discounts on marketable securities | 338 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 2,089 | 4,116 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's D&A?
- Bicara Therapeutics (BCAX) reported D&A of $44K in Q1 2026.
- How has Bicara Therapeutics's D&A changed year-over-year?
- Bicara Therapeutics's D&A increased by 131.6% year-over-year, from $19K to $44K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Bicara Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude